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There are four stages to improving medical therapeutics: 1)
the discovery of new therapies, 2) the application of such
treatments to humans, 3) the demonstration of their ther-
apeutic efficacy in clinical trials, and finally, 4) the applica-
tion of efficacious therapies during routine medical practice.
Relative to the other stages, this last important step is
supported by relatively few resources, possibly owing to
the implicit assumption that physicians and medical
systems routinely adopt efficacious therapies without the
need for measurement or support. However, in almost
every instance in which medical practice is examined,
treatment and outcomes vary widely, and therapies and
clinical trials identified as beneficial are often surprisingly
underutilized.
Lacking adequate resources to measure the effectiveness
of medical practice, hospitals, health-care purchasers, gov-
ernments and the media often turn to administrative data.
In this issue of the Journal, Tu et al. (1) suggest a measure
of medical effectiveness based on Ontario administrative
data. Analyzing 52,616 patients hospitalized for acute myo-
cardial infarction between 1994 and 1997, they identify 11
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claims descriptors most associated with 30-day and 1-year
mortality. The work goes on to externally validate the
findings, demonstrating that these same descriptors and
their corresponding regression model coefficients are simi-
larly associated with mortality in administrative data from
Manitoba and California.
In choosing from among 43 candidate variables for the
final Ontario prediction rule, these researchers use reason-
able selection criteria, including previously published risk
factors, strength of association with mortality and clinical
intuition. Two other considerations that may add to the
suitability of claims diagnoses in mortality comparisons
include the likelihood that a diagnosis represents a coexist-
ing illness rather than a complication, and the potential for
“gaming” of the variable. A significant concern regarding
the use of claims data in mortality comparisons involves the
difficulty in discerning diagnoses present on admission from
those that accrue during hospitalization. In the latter case,
the inclusion of complications in regression models gives
hospitals credit for complications. For example, a patient
with a large myocardial infarction who is not treated with
reperfusion therapy may go on to develop shock or conges-
tive heart failure, and these diagnoses would increase ex-
pected mortality in regression models, effectively “lowering
the bar” for the involved hospital and masking less effective
care. Claims data from Ontario may potentially avoid this
dilemma, because hospitals in this province are required to
add an additional level of detail to hospital discharge
diagnoses that identifies them as either preexisting or
occurring after hospital admission, and only diagnoses
identified as present on admission are used for risk adjust-
ment. For systems lacking the level of detail available in
Ontario, diagnoses in the suggested prediction rules such as
acute renal failure and cardiac dysrhythmias may represent
complications for which hospitals “earn credit” as noted
earlier.
Regarding gaming, in settings where hospital claims are
used to rank health-care providers, public scrutiny may
encourage providers to code high risk diagnoses whenever
possible. Such a strategy would lead to an apparent im-
provement in outcomes due to manipulation of hospital
discharge abstracts, rather than any real improvement in
care. The reporting of diagnoses, such as shock, present
among 2.5% of patients in the Ontario data, and approxi-
mately 7% of patients in clinical data, should be monitored
at the hospital level to differentiate actual improvements in
mortality from “coding creep,” or increased specification of
mortality model components (2).
These authors consider the ability of their models to
account for mortality differences through a variety of mea-
sures, including calibration, or a comparison of actual to
expected mortality, for 10 subgroups sorted by increasing
risk. Most prominently featured is the area under the
receiver operating characteristic (ROC) curve or c-statistic.
This measure divides patients into two groups, alive or dead,
and examines how often the model assigns higher mortality
risk to the patient that died for all potential pairs of patients.
A value of 1 represents discrimination 100% of the time or
perfect discrimination, while a value of 0.5 implies discrim-
ination 50% of the time or similar discrimination to that of
a coin toss. The values herein of 0.77 to 0.79 are reasonably
good for mortality models. In considering these measures,
one should be aware that the inclusion of complications in
mortality models improves model performance characteris-
tics such as ROC areas and calibration despite obscuring the
identification of most effective care. Thus, deciding if data
are suitable for outcomes comparisons should also consider
factors beyond these performance measures.
Most remarkable is the finding that the Charlson index (a
group of 12 illnesses found to be associated with 1-year
mortality among 559 New York University general medi-
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cine patients over a decade ago) had a similar association
with mortality as the newly developed index, with ROC
areas of 0.74 and 0.77 (3). This finding supports the notion
that comorbid illness remains important across time, health
systems and a broad array of medical conditions.
The present work of Tu et al. (1) provides us with
prediction rules that have been developed and validated in
three separate systems and can be readily applied to claims
data. There are a number of settings where this approach
may be adopted. First, the Ontario variables should be
considered as candidate variables in the design of prospec-
tive data collection tools. Second, because the variables are
based on the more broadly applied International Classifica-
tion of Diseases, rather than the Clinical Modification
version specific to the U.S. system, the prediction rule could
be used in international comparisons of acute myocardial
infarction care. These variables and their corresponding
coefficients should also be useful in settings where relatively
few patients are considered, such as the specification of
mortality risk at the individual health-care provider level. In
situations involving larger numbers of patients, such as
regional or national comparisons, the Ontario conditions
should be considered as individual variables without corre-
sponding coefficients to obtain the strongest association
with mortality.
Although the Ontario prediction rules may be applied to
a number of situations, a fundamental question remains
unanswered. Do mortality comparisons based on adminis-
trative data help identify effective medical care? In order to
answer this question, the authors suggest as a next step the
comparison of mortality-adjusted hospital rankings to hos-
pital use of therapies supported by clinical trials. Studies in
the past that have compared evidence-based care to mortal-
ity rankings have found better care among lower mortality
providers. However, these correlations have not been uni-
form, as the occasional therapeutic practice at higher rated
hospitals has implied less optimal care. For example, the
Cooperative Cardiovascular Project identified lower use
of reperfusion therapies among “America’s 60 best hos-
pitals” despite better rankings for acute myocardial in-
farction mortality (4). Until mortality comparisons based
on administrative data are found to reliably identify
better medical practice, their findings should be consid-
ered provisional, providing opportunities in which pro-
cesses and outcomes may be considered in more detail to
verify or refute the level of medical effectiveness implied
by mortality estimates.
Numerous studies of routine medical practice have doc-
umented substantial underuse of randomized trial-
supported therapies. For example, only about one half of
Medicare acute myocardial infarction patients who were
“ideal candidates” for beta-blockers or reperfusion received
such therapies (5). If these efficacious therapies were pro-
vided to all patients, their practical impact might be dou-
bled. In bridging the considerable gap between clinical trial
evidence and routine medical practice, what are the next
steps? The refinement of claims data to identify effective
medical therapy using the Ontario approach remains a
practical and reasonable first step. This approach, however,
should be considered an interim solution. In order to resolve
fully the gulf between evidence from clinical trials and
medical practice, information needs are much greater than
current claims data can provide. Physicians and other
health-care providers need to know if and when effective
medical therapies are being employed, whether treatments
found to be efficacious in clinical trials are similarly effective
when applied to the general population and where resources
may be best directed to improve care.
Recent experience during a European Society of Cardi-
ology/American College of Cardiology exchange program
suggested that we are at the threshold of a fundamental
change in medical care. Despite differences in language and
customs across countries, one feature that remained consis-
tent across U.S. and European hospitals was identical
computer technology. This new international electronic
standard has placed information systems capable of measur-
ing effectiveness within the reach of health systems in most
of the developed world. With such innovation, the vast array
of data generated during routine practice may actually be
used to systematically improve practice. Rather than further
refining claims data, our greatest efforts should involve
redirecting the traditional medical practice of meticulously
recording information in free text and paper-based systems
toward the specification of such information in common
electronic formats suitable for comparison across hospitals
and health systems. This reconfiguring of the medical
information process should be supported by the integration
of information from other medical care activities, including
scheduling, pharmaceutical administration and test results
reporting. These efforts must also be supported by the
development of sensible standards to protect confidentiality
without overly obscuring information such that medical care
cannot be evaluated. The featured Ontario work demon-
strates that the tools exist to convert regional electronic
medical data into information about medical effectiveness.
Ultimately, relatively coarse tools such as administrative
data comparisons will be replaced by systems that can
directly monitor and guide medical effectiveness. Such an
enhancement to the final critical step of therapeutic devel-
opment will ensure that efficacious therapies proliferate
beyond clinical trials so that all of society may benefit from
medical discovery.
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